Novartis, Par Settle Patent Suit Over Lotrel

Law360, New York (February 12, 2009, 12:00 AM EST) -- Novartis International AG and Par Pharmaceutical Cos. Inc. have moved to dismiss a patent suit over Par's proposed generic version of Novartis' billion-dollar hypertension drug Lotrel.

On Wednesday, Judge Harold A. Ackerman of the U.S. District Court for the District of New Jersey signed off on a stipulation of dismissal the two companies filed last week.

The stipulation does not indicate whether there was a settlement in the case, and representatives for both Novartis and Par could not be reached for comment.

The case began in...
To view the full article, register now.